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Introduction
Breast cancer is the most common malignant tumour in 
women. Estimates for 2008 indicate that 1.38 million 
women were diagnosed and 0.46 million died from the 
disease worldwide [1]. Currently, the incidence in the 
developed and developing world is similar but, whereas 
incidence rates are tending to plateau or decline in the 
West, they are increasing in the developing world, presu-
mably related to changes in dietary and repro  ductive 
behaviours and ageing populations [1]. Total mortality 
from breast cancer is already higher in the developing 
world [1]. Whilst mortality is declining in most western 
countries, it is estimated that it will increase by over 
100% in developing countries by 2020 [2].
Whereas less than one-third of women diagnosed with 
breast cancer in developed countries die from the 
disease, this proportion reaches over two-thirds in 
developing countries and is directly related to income per 
capita (Figure 1a) [1,3]. Berry and colleagues [4] developed 
a series of independent statis  tical models of breast cancer 
incidence in order to determine the relative importance 
of the contribution of mammographic screening and 
adjuvant therapy to the marked decline in breast cancer 
mortality in the majority of developed countries. Th  ey 
estimated the mortality decline was related equally to 
screening and therapy and that mortality would increase 
in countries with limited facilities for screening and 
treatment (Figure 1b).
Early detection
Th   e analyses of Berry and colleagues and trials of screen-
ing indicate the importance of early detection by mam-
mo  graphy. However, where mammographic screening is 
introduced into a country gradually, improvements in 
outcome are also seen in the non-screened group, which 
may, in part, be related to a general increase in awareness 
of the importance of early treatment [5,6]. Whilst 
randomised trials of breast self-examination versus no 
examination do not demonstrate the eﬀ  ectiveness of the 
intervention compared with women simply being made 
aware of breast examination [7], these studies do not 
address the issue of lack of awareness or of barriers to 
women presenting early rather than late. In many 
developing countries, the introduction of mammographic 
screening is currently not possible because of expense, 
the relatively low incidence of breast cancer and low age 
of diagnosis. Th   us, the Early Resource Allocation Panel of 
the Breast Health Global Initiative (BHGI) produced 
guidelines suggesting a graded system of introduction for 
breast awareness and mammography based on whether 
the health care system was basic, limited, enhanced or 
maximal [8,9]. In countries with basic and limited 
resources they suggest the widespread introduction of 
culturally sensitive, linguistically appropriate, local 
education programmes to teach breast health awareness 
and awareness with mammography in countries with 
enhanced or maximal health care systems. An example is 
the Mumbai area in India, where mammography is not 
available but with education in the city two-thirds of 
women present with stage I and II breast cancer 
compared to only one-third in local rural populations 
(R Badwe, personal communication).
Less than optimal treatment
Th  e  diﬃ   culties associated with the introduction of opti-
mal treatment for breast cancer, as deﬁ  ned by western 
standards, are highlighted by the absence or low distri-
bution of radiotherapy and systemic therapy services in 
the developing world. In Africa, for example, radio-
therapy services were available in only 17 of 44 countries 
surveyed [10]. Th   e BHGI guidelines for the introduction 
of radiation therapy suggest use of cheaper and simpler 
cobalt machines compared with linear accelerators or 
shorter schedules. Th   e Programme for Action for Cancer 
Th  erapy has introduced over 400 programmes to help 
introduce cancer and, more speciﬁ  cally,  radiotherapy 
services in the developing world [11]. Th   e BHGI has also 
issued guidelines for the introduction and evaluation of 
local and systemic therapies in relation to resources. For  © 2010 BioMed Central Ltd
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recommend radical mastectomy without radiation therapy 
and simple systemic treatment such as CMF (cyclo  phos-
phamide, methotrexate and ﬂ  uorouracil)  chemo  therapy 
and tamoxifen (oophorec  tomy in premeno  pausal women) 
[12].
Questions arise concerning the aﬀ  ordability of treat-
ment, particularly long-term systemic treatment. Aﬀ  ord-
ability may be deﬁ   ned as the number of days’ wages 
required for the lowest paid government worker to 
purchase a 1-month supply of treatment. Taking blood 
pressure treatment with aspirin, atenolol, an angiotensin-
converting-enzyme inhibitor and a statin as an example, 
Mendis and colleagues [13,14] calculated that treatment 
costs per month would take 5.4 days of salary for a middle 
income country such as Pakistan and 18.4 days for a low 
income country such as Malawi. Certain important but 
expensive treatments, such as herceptin, are simply not 
aﬀ  ordable in developing countries [15]. Such problems 
may be circumvented by introducing shorter treatment 
durations, intermittent treatments, diﬀ  erential  pricing 
schemes and the use of low cost medicines, including 
generics, and, unfortunately, stratifying treatment options 
by available resources as suggested in BHGI guidelines 
[16]. Another approach is to test completely new low cost 
treatments. For example, Badwe and colleagues [17], 
based on information that primary breast operations in 
the luteal phase of the menstrual cycle improved 
outcome in their previous studies, demonstrated that a 
single injection of hydroxyprogesterone (500 mg) 4 to 14 
days preoperatively improved overall 5-year survival in 
women with node-positive disease by an absolute value 
of 8.9%. Another approach is to use relatively low cost 
approaches to predicting the necessity for treatments 
overall. For example, Cuzick and colleagues [18] 
demonstrated that a formula based on immunochemical 
estimation of oestrogen and progesterone receptors, 
HER2 and Ki67 with clinical features was as predictive as 
the Oncotype DX and potentially much cheaper.
Conclusion
Th   ere is little doubt that because of demographic changes 
and lack of access to early diagnosis and treatment in the 
developing world there will be continuous marked 
increases in the incidence of and mortality from breast 
cancer. It is crucial that there is a widespread increase in 
educational programmes to increase awareness and early 
presentation and the introduction of screening where 
aﬀ  ordable.  Th  e BHGI guidelines [8,9,11,16] are useful 
indicators for governments of the potential sequence of 
developments for early detection and treatment. It 
appears, to date, that systemic treatments, mainly 
developed in developed countries, are eﬀ  ective  in 
developing ones. For example, Love and colleagues [19] 
demonstrated the value of adjuvant tamoxifen and 
oophorectomy in Vietnam and fulvestrant appears 
equally active for advanced breast cancer in Japan and 
North America [20,21]. However, Richard Love wisely 
points out that therapies developed in high income 
societies may not always be directly transferred without 
evaluation of their eﬀ  ectiveness, including drug metabo-
lism and cultural and psychosocial issues [9] and the 
operation of health care systems. Ragaz and colleagues 
[22] and this issue highlight that the introduction of early 
diagnosis and treatment has not only improved survival 
between provinces in Canada, but may be responsible for 
improved survival in urban Shanghai compared with 
rural China.
Figure 1. More deaths from breast cancer in the absence of early 
diagnosis and systemic treatment. (a) Income diff  erences and 
diff  erences between age-adjusted incidence and mortality (from 
[3] with permission). (b) Model of the estimates of the contribution 
of mammographic screening and systemic adjuvant therapy to the 
decline of mortality from breast cancer in developed countries and 
the eff  ect of absence of both modalities (from [4] with permission).
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